XML 19 R4.htm IDEA: XBRL DOCUMENT v3.23.4
Interim Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]            
Research and development, net $ (1,612) $ (1,953) $ (4,594) $ (5,852) $ (7,736) $ (6,153)
General and administrative (932) (1,521) (3,193) (4,361) (5,545) (5,204)
Operating loss (2,544) (3,474) (7,787) (10,213) (13,281) (11,357)
Financing income, net 98 6 201 43 118 44
Capital loss         (5)
Net loss $ (2,446) $ (3,468) $ (7,586) $ (10,170) $ (13,168) $ (11,313)
Basic net loss per share $ (0.21) $ (0.49) $ (0.79) $ (1.43) $ (1.81) $ (1.59)
Diluted net loss per share $ (0.21) $ (0.49) $ (0.79) $ (1.43) $ (1.81) $ (1.59)
Basic weighted average common shares outstanding 11,707,317 7,108,133 9,653,337 7,108,133 7,260,344 7,108,133
Diluted weighted average common shares outstanding 11,707,317 7,108,133 9,653,337 7,108,133 7,260,344 7,108,133